CARE Ratings has reaffirmed Vimta Labs' long-term rating at 'CARE A' with a 'stable' outlook and affirmed the company's short-term rating at 'CARE A1'. According to reports from Business Standard, the agency cited the company's established position in the contract research and testing organisation (CRTO) industry, backed by a seasoned management team with over four decades of industry experience. The latest rating confirmation includes comprehensive coverage across multiple facility types and tenors, demonstrating the agency's confidence in the company's creditworthiness across various funding structures.
The company demonstrated strong financial performance in FY26, driven by robust growth in its pharmaceutical research and testing business and improved operational efficiencies. As reported by Business Standard, Vimta achieved a profit before interest, lease rentals, depreciation, and taxation (PBILDT) margin of 35.26% and a profit after taxation (PAT) margin of 18.86% during the year. The company also reported 11.38% rise in net profit to ₹21.04 crore and 11.80% increase in revenue to ₹109.07 crore in Q1 FY27 compared with Q1 FY26.
According to Business Standard, the ratings are supported by the company's healthy capital structure, strong debt protection metrics, negligible reliance on external borrowings, and comfortable liquidity position. The company maintains nil utilisation of working capital limits and holds cash and cash equivalents of ₹69 crore as on 31 March 2026. Vimta Labs operates with a large laboratory space of nearly 600,000 square feet, equipped with modern equipment and infrastructure, covering various sectors including pharmaceuticals, agrochemicals, food and agriculture products, medical devices, personal care items, electrical and electronics, and environment studies.
As reported by Business Standard, the stock price rose 0.43% to currently trade at ₹657.40 on the BSE following the rating announcement. The company has undertaken significant investments in its Biologics segment, which remains in the development phase and is expected to commence meaningful revenue generation by FY27-end.
